438 related articles for article (PubMed ID: 27479789)
1. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
2. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
4. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
5. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
9. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
[TBL] [Abstract][Full Text] [Related]
10. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
11. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
13. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
14. Radiopharmaceuticals for somatostatin receptor imaging.
Mikołajczak R; Maecke HR
Nucl Med Rev Cent East Eur; 2016; 19(2):126-32. PubMed ID: 27479790
[TBL] [Abstract][Full Text] [Related]
15. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
16. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP
J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438
[TBL] [Abstract][Full Text] [Related]
20. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
